High sensitivity C-reactive protein in clinical practice.
High sensitivity C-reactive protein in clinical practice.
复制标题
DOI：
10.1111/j.1541-9215.2003.02109.x
复制
发表时间：
2003-01-01
期刊：
影响因子：
--
通讯作者：
Ridker, Paul M
中科院分区：
文献类型：
--
作者：
Torres, Jose L;Ridker, Paul M
随着越来越多低密度脂蛋白胆固醇水平的患者被诊断为动脉粥样硬化，研究已经转向炎症标志物，试图改善全球心血管风险预测。这些标记包括细胞因子、细胞粘附分子和急性期反应物，如高灵敏度c反应蛋白（一种先天免疫反应蛋白）。当用新的高灵敏度测定法测量时，高灵敏度c反应蛋白水平已被证明可以预测所有低密度脂蛋白胆固醇水平、所有弗雷明汉风险评分水平和所有代谢综合征水平的未来心血管风险。在表面健康的男性和女性中，3mg /L的高敏感c反应蛋白水平分别区分了未来心血管疾病的低、中、高风险人群。在临床实践中，高敏感性c反应蛋白应与脂质评估一起作为整体风险评估的一部分。提高对心血管风险的认识，可以提高对旨在预防未来心血管事件的生活方式和药物干预措施的依从性。
As a growing number of patients with low low-density lipoprotein cholesterol levels are diagnosed with atherosclerosis, research has shifted toward markers of inflammation in an attempt to improve global cardiovascular risk prediction. These markers include cytokines, cell adhesion molecules, and acute phase reactants like high sensitivity C-reactive protein, an innate immune response protein. When measured with new high-sensitivity assays, levels of high sensitivity C-reactive protein have proven to predict future cardiovascular risk at all levels of low-density lipoprotein cholesterol, at all levels of the Framingham Risk Score, and at all levels of the metabolic syndrome. Among apparently healthy men and women, levels of high sensitivity C-reactive protein of 3 mg/L distinguish between those at low, moderate, and high risk for future cardiovascular disease, respectively. In clinical practice, high sensitivity C-reactive protein should be used along with lipid evaluation as part of global risk assessment. Improved knowledge of cardiovascular risk should lead to improved compliance with both lifestyle and pharmacologic interventions designed to prevent future cardiovascular events.